Camptothecin analogues, conjugates and methods of use
US-2024269309-A1 · Aug 15, 2024 · US
Antibodies with improved half-life in ferrets
US9738702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9738702-B2 |
| Application number | US-201514656149-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2015 |
| Priority date | Mar 14, 2014 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models.
First claim
Opening claim text (preview).
We claim: 1. An isolated antibody, comprising a ferret IgG Fc region modified relative to a corresponding unmodified ferret IgG Fc region wherein the ferret IgG Fc region comprises a substitution at amino acid residue 252 selected from S252Y or S252M and substitutions S254T and T256E numbered according to the EU index as in Kabat, wherein the in vivo half-life of the modified antibody, is increased by about 2 fold to about 3.5 fold in a ferret compared with the corresponding unmodified antibody. 2. The antibody according to claim 1 , wherein the antibody is a chimeric, ferret, ferretized, or a ferret veneered antibody. 3. The antibody according to claim 1 , wherein the antibody specifically binds to Respiratory Syncytial Virus F glycoprotein. 4. The antibody according to claim 3 , comprising a heavy chain constant region sequence set forth in one of SEQ ID NOs: 1-4. 5. The antibody according to claim 3 , further comprising a light chain constant region sequence set forth in SEQ ID NO: 5. 6. An isolated antibody comprising: a. a human or humanized Fab, and b. a ferret IgG Fc region modified relative to a corresponding unmodified ferret IgG Fc region wherein the ferret IgG Fc region comprises a substitution at amino acid residue 252 selected from S252Y or S252M and substitutions S254T and T256E numbered according to the EU index as in Kabat, wherein the in vivo half-life of the modified antibody is increased by about 2 fold to about 3.5 fold in a ferret compared with the corresponding unmodified antibody.
Assignees
Inventors
Classifications
- C07K16/11Primary
Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title
Increased effector function due to an Fc-modification · CPC title
CH2 domain · CPC title
Constant or Fc region; Isotype · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9738702B2 cover?
- The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/11. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).